



Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System / Raschi R.; Mazzarella A.; Antonazzo C.; Bendinelli N.; Forcesi E.; Tuccori M.; Moretti U.; Poluzzi E.; De Ponti F. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - STAMPA. - 14:2(2019), pp. 205-221. [10.1007/s11523-019-00632-w]

ARCHIVIO ISTITUZIONALE  
DELLA RICERCA

## Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

*Availability:*

This version is available at: <https://hdl.handle.net/11585/721992> since: 2020-02-05

*Published:*

DOI: <http://doi.org/10.1007/s11523-019-00632-w>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

This is the peer reviewed accepted manuscript of:

Raschi E, Mazzearella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F.

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.

Target Oncol. 2019 Apr;14(2):205-221.

The final published version is available online at:

<https://doi.org/10.1007/s11523-019-00632-w>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

*This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)*

***When citing, please refer to the published version.***

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA Adverse Event Reporting System

*Running heading: Immune checkpoint inhibitors in the FDA Adverse Event Reporting System*

Emanuel Raschi<sup>1</sup>, Alessandra Mazzearella<sup>1</sup>, Ippazio Cosimo Antonazzo<sup>1\*</sup>, Nicolò Bendinelli<sup>1\*</sup>, Emanuele Forcesi<sup>1</sup>, Marco Tuccori<sup>2</sup>, Ugo Moretti<sup>3</sup>, Elisabetta Poluzzi<sup>1</sup>, Fabrizio De Ponti<sup>1</sup>

<sup>1</sup> Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Via Irnerio 48, 40126 Bologna, Italy

<sup>2</sup> Unit of Adverse Drug Reactions Monitoring, Tuscan Regional Centre of Pharmacovigilance, University Hospital of Pisa, Via Roma 55, 56126, Pisa, Italy

<sup>3</sup> Department of Public Health and Community Medicine, University of Verona, Verona, Italy

\* equally contributed

## Corresponding author:

Emanuel Raschi, MD, PhD

Alma Mater Studiorum - University of Bologna

Department of Medical and Surgical Sciences

Via Irnerio, 48 - 40126 Bologna BO Italy.

Tel: +39 – 051–20 91802. Fax: +39-051-2091780.

e-mail: [emanuel.raschi@unibo.it](mailto:emanuel.raschi@unibo.it)

ORCID ID: 0000-0003-0487-7996

**Word count:** 4551

**Number of tables:** 4

**Number of figures:** 3

**Number of references:** 63

**Supplementary material:** 2

## Abstract

**Background** Different immune-related adverse events (irAEs) were described with immune checkpoint inhibitors (ICIs), including blockers of cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 or its ligand (PD1/PDL1), although their global safety is incompletely characterized.

**Objective** To characterize spectrum, frequency and clinical features of ICI-related adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS).

**Patients and Methods** AEs from FAERS (up to June 2018) recording ICIs (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab) as suspect were extracted. Comprehensive disproportionality analyses were performed through the reporting odds ratio (ROR) with 95% confidence interval (95%CI), using other oncological drugs as comparison. An overview of systematic reviews (OoSrs) was also undertaken to identify irAEs with consistent positive associations.

**Results** ICIs were recorded in 47,266 reports, submitted mainly by consumers receiving monotherapy with anti-PD1/PDL1 drugs. Three areas of toxicity emerged from both disproportionality and OoSrs (33 studies): endocrine (N=2,863; ROR=6.91; 95%CI=6.60-7.23), hepatobiliary (2,632; 1.33; 1.28-1.39), respiratory disorders (7,240; 1.04; 1.01-1.06). Different reporting patterns emerged for anti-CTLA4 drugs (e.g., hypophysitis, adrenal insufficiency, hypopituitarism and prescribed overdose) and anti-PD1/PDL1 (e.g., pneumonitis, cholangitis, vanishing bile duct syndrome, tumour pseudoprogression and inappropriate schedule of drug administration). No increased reporting emerged when comparing combination with monotherapy regimen, but multiple hepatobiliary/endocrine/respiratory irAEs were recorded.

**Conclusions** This parallel approach through contemporary post-marketing analysis and OoSrs confirmed that ICIs are associated with a multitude of irAEs, with different reporting pattern between anti-CTLA4 and anti-PD1/PDL1 medications. Close clinical monitoring is warranted to early diagnose and timely manage irAEs, especially respiratory, endocrine and hepatic toxicities, which warrant further characterization: patient- and drug-related risk factors should be assessed through analytical pharmaco-epidemiological studies and prospective multicenter registries.

## Keypoints

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
  - 61
  - 62
  - 63
  - 64
  - 65
- As anticipated from pre-approval clinical trials, immune checkpoint inhibitors (ICIs) are associated with large post-marketing reporting of variegate immune-related adverse events (irAEs), occurring virtually at any organ or tissue.
  - Gastrointestinal disorders, hypophysitis and adrenal insufficiency were more frequently reported with anti-CTLA4 drugs, whereas thyroid dysfunction, pneumonitis, cholangitis, vanishing bile duct syndrome with anti-PD1/PDL1 agents.
  - No increased reporting emerged when comparing combination with monotherapy regimen, but co-reporting of hepatobiliary/endocrine/respiratory irAEs were recorded.
  - This comprehensive analysis of the FDA Adverse Event Reporting System, together with a structured appraisal of published systematic reviews, identified endocrine, hepatic and respiratory toxicities as emerging safety priorities.
  - These toxicities should be further characterized to verify the existence of a class effect (liver injury) and assess incidence and elucidate patient- and drug-related risk factors.

## 1 Introduction

1  
2 Immunotherapy is changing the therapeutic landscape of several solid tumours. Immune  
3  
4 checkpoint inhibitors (ICIs) represent the cornerstone of these novel targeted approaches: they increase  
5  
6 antitumor immunity through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell  
7  
8 death 1 (PD1) or its ligand (PDL1) [1, 2]. Ipilimumab, the first anti-CTLA-4 drug, caused a paradigm shift in  
9  
10 drug development of these drugs: lessons learnt with its novel response kinetics and delayed separation of  
11  
12 Kaplan–Meier survival curves led to change primary outcomes from response-based end points (overall  
13  
14 response rate or progression-free survival) to overall survival [3].

15  
16 From a safety standpoint, the increased activity of the immune system results in unique and distinct  
17  
18 spectrum of side effects, the so-called immune-related adverse events (irAEs), which can affect different  
19  
20 organs, especially gastrointestinal tract, endocrine glands, lung, and liver. Although irAEs are mild to  
21  
22 moderate in severity and usually manageable [4], fulminant cases have been described [5], and the wide  
23  
24 range of potential clinical manifestations requires multidisciplinary collaborative team, with several  
25  
26 unresolved questions [6], including recommendations for mitigating and management of specific toxicities  
27  
28 [7], and optimal algorithm for personalized shut-off treatment [8]. Pre-approval trials have shown better  
29  
30 safety than chemotherapy, although combination of both CTLA4 and PD1 inhibitors (acting on distinct  
31  
32 lymphocyte subtypes and at different sites) caused a higher incidence and a broader spectrum of irAEs [9].

33  
34 Considering that ICIs have entered clinical practice with great expectations, post-marketing  
35  
36 monitoring is a crucial aspect to reach a well balanced view, and the term immuno-vigilance was recently  
37  
38 coined [10]. Pivotal trials cannot fully assess rare AEs because of inconsistent reporting across trials [11],  
39  
40 and case reports from the literature can only provide a partial epidemiological picture [12]. The analysis of  
41  
42 international spontaneous reporting systems allows a broader view, by collecting unpublished reports of  
43  
44 AEs submitted worldwide occurring in real-world unselected oncological patients with comorbidities and  
45  
46 poly-pharmacotherapy, even in the long-term; this ensures rapid detection of even rare irAEs and emerging  
47  
48 clinical entities such as myocarditis and coronary toxicity [13, 14], especially for biological/biotechnological  
49  
50 medicinal products with peculiar pharmacokinetics-pharmacodynamics [15].

51  
52 In this pharmacovigilance study, we analyzed AEs submitted to the US Adverse Event Reporting  
53  
54 System (FAERS), in order to characterize their current safety profile (frequency, spectrum, clinical features),  
55  
56 alone and in combination. Moreover, emerging toxicities were classified with relevant level of priority for  
57  
58 further research, based on a structured literature appraisal.  
59  
60  
61  
62  
63  
64  
65

## 2. Methods

### 2.1 Study concept and design

The study was conceived as an observational, retrospective pharmacovigilance study combined with literature appraisal to identify (expected or previously-unknown) toxicities to be prioritized for further research (**Figure 1**). The former was designed as a disproportionality analysis based on unsolicited reports submitted to FAERS, whereas the latter was carried out as purposive literature search for systematic reviews of randomized controlled trials (RCTs), now referred to as overview of systematic reviews (OoSrs). This mixed approach compared two different real-world data (those from observational practice and those from RCTs) and would allow to: a) identify previously-unknown safety issues, 2) characterize known toxicities, 3) provide a public health perspective to recognized irAEs.

#### 2.2.1 FAERS: features, acquisition and processing

FAERS is the US repository of AEs and medication errors spontaneously submitted by healthcare professionals, patients and manufacturers, gathering worldwide reports (including European reports potentially related to serious events and other non-US non-European data). In the recent past, FAERS and other spontaneous reporting systems were exploited in a number of post-marketing drug safety studies to assess both short- and long-term AEs for heterogeneous pharmacological classes [16], including biological products [17-20]. FAERS is particularly attracting among international pharmacovigilance databases because it covers a heterogeneous catchment area (allowing broader generalization of findings) and offers public access to raw data that can be downloaded in a format suitable for customized analyses [21]. Moreover, previous studies have demonstrated great accuracy in early detection of safety issues, especially for newly-approved drugs (i.e., on the market since no more than 5 years) [22], as well as to monitoring AEs with low/rare background incidence [23].

Publicly released version of FAERS was downloaded from relevant website [from the first quarter (Q1) of 2004 through Q2 of 2018]. Before performing customized statistical analyses, FAERS was processed for data quality, including removal of duplicates (i.e., reports with overlaps in 3 out of 4 key fields, namely event date, age, gender and Reporter Country), and standardization of drug names into relevant active substances [24]. AEs can be analyzed through the standardized Medical Dictionary for Regulatory Activities (MedDRA) terminology (version 19); in FAERS, they are coded in terms of Preferred Terms (PTs), which identified specific signs/symptoms of a given clinical entity; the hierarchical structure of MedDRA allows grouping PTs (high specificity) into relevant System Organ Class (SOC, high sensitivity).

### 2.2.2 Disproportionality analysis

Disproportionality analysis is a validated concept in pharmacovigilance that compares the proportion of selected AEs reported for a single drug or drug class (e.g., ICIs) with the proportion of the same AEs for a control group of drugs (e.g., other anticancer agents). The denominator in these analyses is the total number of reports of AEs for each group of drugs. If the proportion of AEs is greater in patients exposed to a specific drug (cases) than in patients not exposed to this drug (non-cases), an association can be hypothesized between the specific drug and the event. Through this so-called *case/non-case* approach, which can be viewed as a case-control analysis, the reporting odds ratio (ROR) with relevant 95% confidence interval (95%CI) was calculated. Disproportionality was considered statistically significant when the lower limit of the 95%CI of the ROR exceeds 1, as recommended [24, 25]. Exposure assessment considered ICIs (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab approved as of June 2018) recorded as “primary suspect” or “secondary suspect”. Therefore, active substances and brandnames represented our criteria to select reports relevant to ICIs.

Pharmacovigilance in oncology is not straightforward, as compared to other medical areas. Frequent use of multiple therapeutic regimens makes it difficult to disentangle side effects of individual drugs *versus* drug–drug interactions *versus* “innocent bystander” effects [26]. Moreover, complexity of patient histories results in high potential for confounding and effect modification (i.e., drug–disease interactions). Finally, the unique benefit–risk consideration may result in a higher threshold for recognizing and reporting AEs. Therefore, different data-mining steps were specifically performed to refine disproportionality analysis and minimize biases as follows: (a) to reduce the likelihood of false positives, disproportionality was calculated only when at least five cases of interest were reported, instead of the traditional signaling criterion of three cases [27]; (b) to provide a clinical perspective, the so-called analysis by therapeutic area (main analysis) was adopted by comparing ICIs versus other oncological drugs (using AEs recording at least one anticancer agent) [28]; (c) to minimize the existence of an “indication bias” (i.e., the indication for which the drugs is prescribed is reported as an AE), reports with overlap between therapeutic indication and reported AE were removed *a priori* from the whole FAERS database (e.g., melanoma reported as AE in patients receiving nivolumab for melanoma).

Analyses were first performed at the SOC level to describe the spectrum of toxicities. Subsequently, key toxicities emerging from the combined assessment with the literature were characterized in terms of specific signs/symptoms (PT level), and ICI regimens (anti-CTLA4 and anti-PD1/PDL1, monotherapy *vs* combination therapy). Additional analyses were also performed to test the consistency of results by considering only data after April 2011 (i.e., considering the affective period on the market of ICIs with the approval of the first-in-class ipilimumab on March 23<sup>rd</sup>, 2011); and comparing ICIs with monoclonal



antibodies (considering the biotechnological nature of these drugs and pharmacological similarities).  
Statistical analyses were performed through PostgreSQL software version 9.5 and Rstudio.

### 2.3 Literature selection and appraisal

The OoSRs was conducted in MEDLINE (via Pubmed, on 29/10/2018) to find SRs of RCTs on the safety of ICI, with restriction to the English articles published up to June 2018. Detailed criteria for article retrieval (search strategy) and eligibility are provided as supplementary material ([Supplementary Material 1](#)).

This OoSRs adopts an “evidence summary” approach. First, potentially-eligible SRs were assessed for quality by applying the validated AMSTAR tool [29]. Second, SRs were assessed for actual eligibility as follows: only direct comparisons between ICIs (as a class or as a single drug) and chemotherapy were selected (indirect network meta-analyses were excluded); meta-analysis without SRs (e.g., pooled analysis) or meta-analysis on the overall safety without specifying/separating AEs in terms of affected organ/system (e.g., fatal irAEs) were excluded. Third, risk estimates were extracted for the various safety outcomes, and used to assess study results. If statistically-significant odds ratio/hazard ratio was found, the study was deemed as “positive”, namely it demonstrated an increased occurrence/risk of a given AE with ICIs; “negative” studies were those with statistically-significant reduced occurrence/risk with ICIs; “neutral” studies were defined when there was no evidence of significant difference (ICIs as effective/safe as comparator) or uncertainty/inconclusive data (e.g., high heterogeneity or inconsistencies across sensitivity analyses). SRs reporting only incidence rates were not evaluated, whereas SRs investigating multiple AEs counted as many-fold as the number of outcomes investigated. In case of multiple analyses, data on grade 3-4 severity were preferred.

Because multiple SRs were identified on the same topic, the totality of SRs was evaluated for robustness (consistency of the findings among SRs in relation to the number of published studies). The following assessment was finally adopted:

**CONSISTENT POSITIVE ASSOCIATION**= more than a half of SRs were concordant in documenting an increased occurrence with ICIs;

**CONSISTENT NEGATIVE ASSOCIATION**= more than a half of SRs were concordant in documenting a reduced occurrence with ICIs;

**NEUTRAL ASSOCIATION**= more than a half of SRs were concordant in documenting no evidence of risk .

**UNCERTAIN ASSOCIATION**= a single SR was available, or conflicting results from two or more SRs.

## 2.4 Definition of the level of priority

Data from literature appraisal and disproportionality analysis were compared for consistency of findings, and four levels of priority were assigned to the different toxicities:

- A) **TOP PRIORITY:** toxicity emerging from disproportionality, with consistent positive association from the OsSRs (i.e., concordance between pre-approval and post-marketing evidence).
- B) **HIGH PRIORITY:** toxicity emerging from disproportionality without data from OsSRs (i.e., only evidence from post-marketing data).
- C) **INTERMEDIATE PRIORITY:** toxicity without disproportionality but consistent positive association from the OsSRs (i.e., only evidence from pre-approval data)
- D) **LOW PRIORITY:** toxicity without disproportionality and neutral/uncertain association from OsSRs.

As anticipated, top and high priorities were further characterized through additional disproportionality analyses in terms of specific signs/symptoms and ICI regimens.

## 3. Results

### 3.1 Descriptive analysis of FAERS and literature appraisal

Over the 15-year period, 16,331,098 FAERS reports were initially processed for drug codification, duplicate removal and aforementioned quality criteria; 8,922,294 reports were finally retained, of which 47,266 (0.53%) included at least one ICI (**Figure 1**). The highest number of reports emerged for nivolumab (N=24,560) followed by ipilimumab (N=13,971) and pembrolizumab (N=10,425). The reported Country was US in 57% of reports. Young adults and subjects aged >65 years old were similarly represented (30-33%), with slight male preponderance (53%, with very similar proportion across various medications) (**Table 1**). The majority of reports were serious (>80%), namely resulting in hospitalization (30%), death (29%) or life-threatening events (3%). A peak in reporting of death was noted for atezolizumab (50%). Notably, consumers were the main source of reports (34%, peaking 79% for atezolizumab), followed by other healthcare professionals and clinicians (30% each). Over years, there was an exponential increase in the number of submitted reports, especially for monotherapy regimen with anti-PD1/PDL1 drugs, with two remarkable peaks in the first quarter of 2017 and second quarter of 2018 (**Figure 2**). *General disorders and administration site conditions* was the SOC with the highest number of reports (16,449), followed by *gastrointestinal disorders* (9,124) and *neoplasms benign. malignant and unspecified (incl cysts and polyps)* (8,773).

The literature search yielded 1,539 studies, which were screened based on aforementioned exclusion criteria: 50 SRs were retained and evaluated for quality, of which 32 were used for quantitative

assessment (**Figure 1**). The overall quality according to the AMSTAR tool was judge high ( $\geq 9$ ) for 25 SRs (**Supplementary Material 1**). Skin (13 studies), gastrointestinal (11), respiratory (10 studies), hepatobiliary (9) and endocrine disorders (8) were the most frequently investigated toxicities. Consistent positive associations finally emerged for endocrine, hepatobiliary, gastrointestinal, skin and respiratory disorders, whereas blood/lymphatic system disorders and general disorders and administration site conditions were deemed to be consistent negative associations.

### 3.2 Disproportionality analysis of FAERS

The disproportionality analysis highlighted six areas of toxicity with statistically significant ROR: *endocrine disorders* (N=2,863; ROR=6.91; 95%CI=6.60-7.23), *hepatobiliary disorders* (2,632; 1.33; 1.28-1.39), *injury, poisoning and procedural complications* (6,776; 1.20; 1.17-1.23), *neoplasms benign, malignant and unspecified (incl cysts and polyps)* (8,773; 1.85; 1.81-1.90), *respiratory, thoracic and mediastinal disorders* (7,240; 1.04; 1.01-1.06), *surgical and medical procedures* (1,298; 1.20; 1.13-1.27) (**Table 2**).

Results were consistent across sensitivity analyses. Specifically, the ROR remained statistically significant when ICIs were compared with monoclonal antibodies, with the exception of *respiratory, thoracic and mediastinal disorders* (ROR=0.92; 95%CI=0.90-0.95); likewise, no major changes to the RORs emerged when the analyses were restricted to the 2011Q2-2018Q2 period, with the exception of *metabolism and nutrition disorders* that reached the threshold for statistical significance (1.13; 1.10-1.17). No disproportionate reporting was found when confronting monotherapy *versus* combination regimens, whereas a different reporting frequency (i.e., statistically significant ROR) emerged when anti-CTLA4 agents were compared with anti-PD1/PDL1 medications for different toxicities, including *endocrine disorders* (1.60; 1.46-1.75), *eye disorders* (1.21; 1.05-1.39), *gastrointestinal disorders* (2.03; 1.93-2.15), *metabolism and nutrition* (1.15; 1.06-1.25), *pregnancy, puerperium and perinatal conditions* (2.28; 1.07-4.86), *skin and subcutaneous tissue disorders* (1.28; 1.19-1.37).

### 3.3 Characterization of emerging toxicities

The combined analysis of FAERS data with literature appraisal highlighted endocrine, hepatobiliary and respiratory disorders as top priorities, whereas *injury, poisoning and procedural complications, neoplasm (benign, malignant and unspecified) disorders, and surgical/medical procedures* emerged as high priorities (**Table 3**). The most frequently reported AEs with disproportionality for all ICIs were

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

*hypothyroidism* (N=777; ROR=6.36; 95%CI=5.85-6.93), *hypophysitis* (594; 20.8; 11.13-38.86), and *adrenal insufficiency* (493; 10.03; 8.88-11.33) for endocrine events, with higher reporting with anti-CTLA4 agents; conversely, thyroid dysfunctions were more frequent with anti-PD1/PDL1 drugs. The ranking was *hepatitis* (420; 3.12; 2.81-3.47), *hepatic function abnormal* (385; 1.55; 1.39-1.72), and *autoimmune hepatitis* (373; 14.23; 11.90-17.00) for liver injuries, with higher reporting for *cholangitis* with anti-PD1/PDL1 medicines (106; 2.51; 2.05-3.07). For respiratory toxicities, disproportionality was found for *pneumonitis* (1,289; 4.06; 3.82-4.32) and *interstitial lung disease* (794; 1.63; 1.52-1.75), with higher reporting frequency for anti-PD1/PDL1 drugs (**Table 4**). Frequency of co-reporting among endocrine, hepatobiliary and respiratory disorders are presented in **Figure 2**.

Among toxicities receiving high priority the most frequently reported AEs were: *malignant neoplasm progression* (6,691; 5.94; 5.77-6.12), *product use in unapproved indication* (1,734; 6.29; 5.94-6.66) and *transfusion* (172; 5.19; 4.37-6.16). Different reporting frequencies were observed for tumour pseudoprogression and inappropriate schedule of drug administration with anti-PD1/PDL1 drugs, and prescribed overdose for anti-CTLA4 agents. The full list of AEs (top and high priorities) with relevant disproportionality is provided in **Supplementary Material 2**.

#### 4. Discussion

To our knowledge, this is the largest comprehensive analysis of post-marketing AEs attributed to ICIs collected from a worldwide pharmacovigilance database: apart from recently-approved avelumab and durvalumab, there is considerable amount of data for nivolumab, ipilimumab, alone and in combination, and pembrolizumab.

Overall, four main findings emerged. First, the exponential increase in the number of AEs, especially since 2017, is noteworthy (ICIs account for 4.8% of total reports with anticancer drugs collected over 13 years) and may be ascribable to various reasons, including the perceived expectations on this immunotherapy that reduced the phenomenon of “clinical inertia” usually observed for non-anticancer drugs, and the progress extension of therapeutic indications in different oncological settings for anti-PD1/PDL1 agents, as well as the case of agnostic approval for pembrolizumab.

Second, the spectrum of irAEs is variegated and, virtually, any organ of tissue can be involved: endocrine systems, liver, lung, gastrointestinal tract and skin, among others, thus emphasizing the importance of timely identification and early personalized management through multidisciplinary tumour board [7, 8]. Notably, Individuals receiving ICIs may experience a unique set of AEs in comparison with first- and second-generation anticancer agents, including monoclonal antibodies: “traditional” biologics are associated with high frequency of reports related to general disorders/administration site condition (owing

1 to the parenteral administration) and predictable toxicities such as infections and neoplasm due to an  
2 immune compromising effect [17-20]. From a pharmacological viewpoint, the question arises as to whether  
3 or not these irAEs are actually predictable. According to RCTs, ipilimumab exhibits a clear dose-dependent  
4 relationship with regards to incidence and severity of irAEs, although the mechanistic basis of toxicity may  
5 vary depending on the damaged organ [30].  
6  
7

8  
9 Third, different reporting frequencies were observed between anti-CTLA4 drugs and anti-PD1/PDL1  
10 agents: gastrointestinal disorders, endocrine and skin disorders were more frequently reported with anti-  
11 CTLA4 drugs (ipilimumab), especially hypophysitis adrenal insufficiency, hypopituitarism and prescribed  
12 overdose, whereas thyroid dysfunction, pneumonitis, cholangitis, tumour pseudoprogression and  
13 inappropriate schedule of drug administration with anti-PD1/PDL1 agents. Similar frequencies were  
14 reported for autoimmune hepatitis and malignant neoplasm progression. These figures are strongly in  
15 agreement with the evidence from previous studies, including SRs of RCTs [11, 31, 32] and other  
16 pharmacovigilance analyses [33-35], thus confirming a close correlation between relative risks/hazard  
17 ratios and disproportionality measures in the modern FAERS [36]. Although the reasons of the observed  
18 reporting pattern remain obscure (and only partially reside on the different mechanisms of action), these  
19 differences in observed toxicities should be carefully considered by clinicians during monitoring to early  
20 intercept serious irAEs and timely optimize treatment strategy.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Fourth, we obtained some unique findings, including: A) no increased reporting with combination  
32 regimen, which is likely to be related to the remarkable reporting frequency of anti-PD1/PDL1 monoclonal  
33 antibodies; B) overlap in co-reporting of endocrine, hepatobiliary and respiratory irAEs, which carries  
34 important implications in clinical monitoring. Based on pre-approval clinical trials data, most of these irAEs  
35 observed with ICIs (especially ipilimumab) typically follow a chronological pattern; they start within the first  
36 8–12 weeks from treatment, with endocrine gland affection usually appearing later at around 9 weeks [37].  
37 Therefore, regular monitoring is required to early assess and manage these toxicities while avoiding  
38 therapy interruption; C) higher reporting of cholangitis and vanishing bile duct syndrome with anti-  
39 PD1/PDL1 monoclonal antibodies. Drug-induced liver injury with ICIs represents an emerging area of  
40 research [38]; recent data from a pharmacovigilance register in France characterized 536 patients with  
41 grade 3 hepatitis and highlighted the importance of liver biopsy to patient-guided approach to avoid  
42 corticosteroids [39]. While previous data suggested that ipilimumab may be associated with higher liver  
43 toxicity rates, as compared to ICIs blocking PD-1 [40], our findings support the existence of a specific  
44 pattern of liver damage for the different ICIs. In fact, while a signal of autoimmune hepatitis consistently  
45 emerged for all checkpoint inhibitors, an increased reporting of cholangitis was found for anti-CTLA4 drugs  
46 (nivolumab), in line with recent case series [41-45]. This form of severe and prolonged liver toxicity can  
47 manifest as “large-ducts or small-ducts cholangitis”, and may have different clinical presentation,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

biochemical evolution and outcome, including secondary sclerosing cholangitis [46]. The occurrence of immune-related cholangitis has been described in subject receiving nivolumab and avelumab, with late onset not only after administration of the treatment, but also after discontinuation of nivolumab [47]. Notably, we also found in FAERS 6 cases of vanishing bile duct syndrome with statistically-significant disproportionality (ROR=3.51; 95%CI=1.48-8.31; supplementary material 2). To our knowledge, this is the first documentation of this pattern of liver injury with ICIs [48]. Taken together, this collated body of evidence call for analytical pharmaco-epidemiological research to assess the risk at the population level and multicenter prospective registries to define the optimal treatment strategy in the individual patient and elucidate risk factors.

Disproportionalities found in our study for medical/surgical procedures, injury/poisoning/procedural complications, and neoplasms received a high priority, as they appear to be previously-unknown safety aspects. The first area of toxicity can be interpreted as underlying cancer-related complications rather than specific drug-related issues, whereas the second area of toxicity is mainly related to aspects dealing with drug administration (over- and under-dose, use in unapproved indications, schedule of administration) and may be a potential consequence of the recent European pharmacovigilance legislation, which modified the definition of adverse drug reaction, by including also issues related to quality aspects, lack of efficacy and “non-normal use” (i.e., abuse, misuse, overdose, occupational exposure, and medication errors) of medicines. We can therefore hypothesize that this regulatory context might result in increased awareness by clinicians on the importance of submitting AEs, thus creating a new type of *notoriety bias*.

Conversely, different clinical reasons may explain the high reporting of AEs potentially suggestive of “drug ineffective” (i.e., malignant recurrence): 1) the aforementioned *notoriety bias*. This hypothesis is supported by recent data highlighting that “drug ineffective” as the most commonly reported AE in FAERS [49]. Additional studies performed on WHO-Vigibase data indicated that clusters of substandard medicines can be identified *via* specific algorithm, although under stringent key prerequisites [50, 51]. Patients’ reporting in social media may complement information from clinicians to describe quality issues and impact on quality of life [52]; 2) the atypical delayed therapeutic response with ICIs, as compared with other targeted anticancer drugs; 3) the recently-described phenomenon of “pseudoprogression” (or even an aggressive pattern of hyperprogression [53]), a distinct immune-related pattern of response, caused by the infiltration of immune cells to the tumor site that can manifest in the form of an apparent relapse (e.g., increase in tumor size, the development of new lesions [54]). Therefore, occurrence of irAEs in early phase of therapy, including the aforementioned pseudoprogression, without apparent clinical benefit might discourage clinicians in pursuing ICI treatment while reporting a potential lack of efficacy. Oncologist should be reminded that therapeutic effect occurs later as compared to the onset of irAEs, and that current data

1 support positive association between these immunological events and survival outcome, as documented  
2 for nivolumab in non-small-cell lung cancer [55-57].  
3

4 Among toxicities with intermediate priority, gastrointestinal and skin disorders warrant brief  
5 discussion. Our data indicated that these safety issues have a non-negligible reporting, but did not result in  
6 significant disproportionality. Clinicians should be reminded that these toxicities do occur and may be even  
7 fatal, especially colitis: initial assessment is crucial when starting ICI treatment, since early management  
8 might prevent progression to more severe toxicity [37].  
9  
10  
11  
12  
13

#### 14 **4.1 Strengths and limitations**

15 We exploited different data sources for safety assessment, including an OoSRs and a contemporary  
16 disproportionality analysis of the largest open-source worldwide database of unsolicited reports. To the  
17 best of our knowledge, only one integrated approach was recently carried out to assess ICI safety, although  
18 it was specifically focused on fatal toxic effects, thus making actual characterization and generalizability  
19 challenging [34].  
20  
21  
22  
23  
24  
25  
26

27 We provided the most updated and comprehensive characterization of irAEs, and further raised  
28 debate on whether or not analysis of spontaneous reporting system can be used to highlight clinical  
29 importance of toxic effects or suggest *foci* of potential drug misuse, unconventional uses and, most  
30 intriguingly, lack of efficacy. Although RCTs remain the best experimental approach to actually inform on  
31 the efficacy of medications, our study provided the public health perspective of toxicities receiving  
32 attention and largely investigated in the recent past, with consistent data: hepatic, endocrine and  
33 respiratory irAEs warrant further prospective assessment to quantify and evaluate actual risk (class effect  
34 versus individual drug), including strategies for optimal management.  
35  
36  
37  
38  
39  
40  
41

42 The vast amount of SRs on irAEs (i.e., multiple reviews on the same topic) is a double-edge sword:  
43 on one hand, this prompted us to verify consistency of findings; on the other hand, it challenged decision-  
44 making process of both clinicians and regulators. Our critical appraisal calls for the need to move from  
45 systematic reanalysis of the existent literature towards a new era of evidence-based medicine through  
46 comparative effectiveness/safety research and combination of multiple sources of real-world data.  
47  
48  
49  
50

51 We acknowledge limitations of FAERS data, in particular the inability to infer causal relationship  
52 between drug exposure and occurrence of AE [21]. The ROR does not inform on the real risk in clinical  
53 practice, mainly because of lack of denominator and under-reporting, but only indicates an increased risk of  
54 AE reporting and not a risk of AE occurrence. Therefore, incidence rates and risk ranking cannot be inferred  
55 from spontaneous reports. These aspects are shared by all pharmacovigilance databases and causal  
56 inferences is also an inherent limitation of cohort studies. We cannot exclude the so-called channeling bias  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (i.e., the possibility that drugs may be differently prescribed in relation to the severity of disease). In fact,  
2 clinical information such as cancer severity and duration is lacking, as well as laboratory and radiological  
3 findings and incomplete reporting of dosing, time to onset, thus making a firm comparison among ICIs  
4 inappropriate [58]. We also recognized that residual confounders may exist, including synergy with  
5 comorbidities and co-medications resulting in potential drug-drug interactions [59], although a number of  
6 measures were planned to minimize biases. We also acknowledge that both false-positive and false-  
7 negative results might exist. We cannot exclude that some AEs such as metastasis do not represent an  
8 indication bias considering that ICIs are also indicated in metastatic settings. Conversely, some AEs might  
9 not be identified because of their rarity or due to methodological issues: disproportionality measures are  
10 interdependent and the literature assessment was not intended to be a systematic review but an OoSs of  
11 RCTs; this may explain the reason why cardiovascular toxicity did not emerge as top priority [60].  
12  
13  
14  
15  
16  
17  
18  
19

20 Notwithstanding these limitations, pharmacovigilance assessment represents an invaluable  
21 opportunity to monitor drug safety and identify new rare signals. We have described the worldwide safety  
22 profile of ICIs in an unselected population; major confounders were accounted for, by applying multiple  
23 “quality criteria” to minimize the likelihood of false positives and other sources of bias (e.g., selection of 5  
24 cases as threshold for calculating disproportionality, removal of reports suggestive of potential indication  
25 bias). There are no reasons to support the existence of stimulated reporting/notoriety bias specifically  
26 referring to a given AE (regulatory warnings are largely homogeneous across pharmacological classes), and  
27 the Weber effect (i.e., a peak in reporting early after approval and a decline hereinafter) was not  
28 demonstrated for oncological drugs, and do not emerged from our data [61].  
29  
30  
31  
32  
33  
34  
35

36 Taken together, our findings and the overall body of the evidence call for proactive immune-  
37 vigilance and should stimulate the conduction of post-authorization studies, as recommended by the  
38 European Medicines Agency, to define the magnitude and extent of irAEs and actual clinical effectiveness,  
39 especially in the metastatic setting. In particular, the oncological area should move beyond adaptive  
40 designs and pragmatic clinical trials to embrace new avenues of Big Smart data [62], such as combining  
41 population-based registries with health record systems [63].  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## 5. Conclusions

Notwithstanding limitations, these real-world FAERS data corroborated the usefulness of pharmacovigilance research and confirmed that irAEs with ICIs may virtually occur at any organ/tissue, including co-occurrences, with different reporting frequencies between anti-CTLA4 drugs (hypophysitis, adrenal insufficiency) and anti-PD1/PDL1 agents (thyroid dysfunction, pneumonitis, cholangitis, vanishing bile duct syndrome).

These findings strengthened the importance of: A) close clinical monitoring of patients to early diagnose and timely manage irAEs, awaiting for the delayed therapeutic response; B) proactive multidisciplinary pharmacovigilance to maintain “real-time” surveillance (especially for recently-approved ICIs such as avelumab, durvalumab, and considering emerging combination regimens with other oncological agents); C) prioritize respiratory, endocrine and liver toxicities to assess and further characterize patient- and drug-related risk factors through analytical pharmaco-epidemiological research and multicenter registries.

## Compliance with Ethical Standards

### Funding

No sources of funding were used to assist in the preparation of this study. Authors at the University of Bologna (ER, EP, FDP) are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).

### Conflict of Interest

Authors declare no potential conflict of interest relevant to the content of the manuscript.

## Figure Captions

**Fig. 1.** Flow Chart to compare FAERS analysis with Literature assessment. ICI: immune checkpoint inhibitor; SRs: systematic reviews.

\* Primary Suspect or Secondary Suspect (see text for details). RCTs: randomized controlled trials.

**Fig. 2.** Time trends of spontaneous reports collected for ICIs, according to the therapeutic regimen. Approval dates and therapeutic indications are also presented, according to the Food and Drug Administration. NSCLC: non-small cell lung cancer

**Fig. 3.** Overlap among AEs reported for endocrine, hepatobiliary and respiratory disorders.

### Supplementary Material 1

Details on literature evaluation: search strategy (with inclusion/exclusion criteria), quality assessment of retained systematic reviews according to the AMSTAR tool, and data extracted from individual systematic reviews.

### Supplementary Material 2

Disproportionality analysis at the Preferred Term level of the four SOCs emerging with statistically-significant ROR in the main analysis and receiving top and high priority based on a parallel literature appraisal.

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 1.** Demographic data. In parentheses relevant percentage is provided (out of total reports). The sum of the number of cases for the different ICIs may be higher than the total number of cases for the drug class because a patient may have received more than one drug (combination regimen).

			ICI as a class	Nivolumab	Ipilimumab	Pembrolizumab	Atezolizumab	Avelumab	Durvalumab
<b>Total Reports</b>			<b>47,266 (%)</b>	<b>24,560 (%)</b>	<b>13,971 (%)</b>	<b>10,425 (%)</b>	<b>2,663 (%)</b>	<b>383 (%)</b>	<b>405 (%)</b>
<b>Geographical distribution</b>	EU		11,437 (24.20)	6,718 (27.35)	3,270 (23.41)	1,816 (17.42)	896 (33.65)	145 (37.86)	149 (36.79)
	Non EU	Africa	83 (0.18)	50 (0.2)	13 (0.09)	19 (0.18)	4 (0.15)		
		Americas	27,134 (57.41)	12,974 (52.83)	9,363 (67.02)	6,058 (58.11)	1,286 (48.29)	143 (37.34)	228 (56.3)
		Asia	7,298 (15.44)	4,150 (16.9)	876 (6.27)	2,197 (21.07)	424 (15.92)	72 (18.8)	20 (4.94)
		Oceania	1,253 (2.65)	636 (2.59)	419 (3)	327 (3.14)	52 (1.95)	23 (6.01)	7 (1.73)
<b>Age group distribution</b>	0-17		118 (0.25)	73 (0.3)	31 (0.22)	21 (0.2)	6 (0.23)		
	18-64		14,261 (30.17)	7,089 (28.86)	5,046 (36.12)	2,968 (28.47)	1,052 (39.5)	171 (44.65)	135 (33.33)
	>65		15,489 (32.77)	7,801 (31.76)	4,013 (28.72)	3,980 (38.18)	1,029 (38.64)	168 (43.86)	166 (40.99)
	UKW		17,401 (36.82)	9,597 (39.08)	4,881 (34.94)	3,456 (33.15)	576 (21.63)	44 (11.49)	104 (25.68)
<b>Patient sex distribution</b>	M		25,247 (53.41)	13,062 (53.18)	7,561 (54.12)	5,629 (54.00)	1,425 (53.51)	205 (53.52)	218 (53.83)
	F		15,329 (32.43)	7,605 (30.96)	4,481 (32.07)	3,699 (35.48)	1,002 (37.63)	158 (41.25)	151 (37.28)
	UKW		6,694 (14.16)	3,893 (15.85)	1,929 (13.81)	1,097 (10.52)	236 (8.86)	20 (5.22)	36 (8.89)
<b>Outcome distribution#</b>	HO		14,034 (29.69)	7,096 (28.89)	5,204 (37.25)	2,567 (24.62)	1,335 (50.13)	226 (59.01)	188 (46.42)
	DE		13,787 (29.17)	8,068 (32.85)	3,014 (21.57)	3,160 (30.31)	521 (19.56)	87 (22.72)	64 (15.8)
	OT		10,560 (22.34)	5,861 (23.86)	3,032 (21.7)	2,138 (20.51)	343 (12.88)	30 (7.83)	63 (15.56)
	LT		1,632 (3.45)	839 (3.42)	423 (3.03)	426 (4.09)	130 (4.88)	21 (5.48)	17 (4.2)
	DS		287 (0.61)	123 (0.5)	51 (0.37)	108 (1.04)	14 (0.53)	1 (0.26)	2 (0.49)
	CA		3 (0.01)		1 (0.01)	2 (0.02)			

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

	UKW		6,966 (14.74)	2,573 (10.48)	2,246 (16.08)	2,024 (19.41)	320 (12.02)	18 (4.7)	71 (17.53)
<b>Reporter's occupation distribution</b>	CN		16,292 (34.47)	6,919 (28.17)	5,085 (36.4)	5,141 (49.31)	167 (6.27)	10 (2.61)	21 (5.19)
	OT		14,241 (30.13)	9,344 (38.05)	5,750 (41.16)	1,736 (16.65)	260 (9.76)	90 (23.5)	90 (22.22)
	MD		14,231 (30.11)	6,855 (27.91)	2,617 (18.73)	3,049 (29.25)	2,108 (79.16)	277 (72.32)	260 (64.2)
	PH		2,284 (4.83)	1,359 (5.53)	453 (3.24)	441 (4.23)	119 (4.47)	6 (1.57)	15 (3.7)
	LW		14 (0.03)	10 (0.04)		4 (0.04)			
	UKW		210 (0.44)	73 (0.3)	66 (0.47)	54 (0.52)	9 (0.34)	(0)	19 (4.69)
<b>Therapeutic regimen</b>	Monotherapy		42,156 (89,19)	19,606 (79,83)	8,903 (63,72)	10,209 (97,93)	2,652 (99,59)	382 (99,74)	404 (99,75)
	Combination		5,110 (10,81)	4,954 (20,17)	5,068 (36,28)	216 (2,07)	11 (0,41)	1 (0,26)	1 (0,25)
<b>Reporting year</b>	Before 2011		68 (0,14)		68 (0,49)				
	2011		652 (1,38)	1 (0)	652 (4,67)				
	2012		1,189 (2,52)	5 (0,02)	1,187 (8,5)				
	2013		1,080 (2,28)	26 (0,11)	1,073 (7,68)				
	2014		2,046 (4,33)	119 (0,48)	1,646 (11,78)	393 (3,77)	3 (0,11)		
	2015		5,157 (10,91)	2,462 (10,02)	2,111 (15,11)	1,295 (12,42)	20 (0,75)		
	2016		10,989 (23,25)	7,037 (28,65)	2,079 (14,88)	2,290 (21,97)	553 (20,77)	6 (1,57)	14 (3,46)
	2017		15,769 (33,36)	9,098 (37,04)	3,245 (23,23)	3,777 (36,23)	1,158 (43,48)	186 (48,56)	136 (33,58)
2018*		10,316 (21,83)	5,812 (23,66)	1,910 (13,67)	2,670 (25,61)	929 (34,89)	191 (49,87)	255 (62,96)	

EU: European Union; UKW: unknown (missing data); F: females; M: males; CA: congenital anomaly; DE: death; DS: disability; HO: hospitalization (initial or prolonged); LT: life-threatening; OT (outcome distribution): other serious (important medical event); OT (reporter's occupation distribution): other health-professional; MD: medical doctor; PH: pharmacist; LW: lawyer; CN: consumer.

\* Up to Q2 (June 2018).

# because different degrees of seriousness may be recorded in a single report, the final level of seriousness was assigned based on the following ranking: death>life-threatening>hospitalization>disability>congenital anomaly>other serious.

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 2.** Primary and secondary disproportionality analyses. In bold: statistically significant disproportionality (i.e., lower limit of the 95%CI of the ROR>1) is shown with a dark background.

Toxicity of interest	ICI vs other anticancer drugs (Q2/2004-Q2/2018)		ICIs vs other anticancer drugs (Q2/2011-Q2/2018)		ICIs vs monoclonal antibodies (Q2/2004-Q2/2018)		monotherapy vs combination (n=42,156)		Anti-CTLA4 monotherapy vs anti-PD1/PDL1 monotherapy (n=8,903)	
	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)
Blood and lymphatic system disorders	3,134	0.48 (0.47-0.50)	3,125	0.54 (0.52-0.56)	3,134	0.46 (0.44-0.48)	2,780	0.99 (0.89-1.11)	513	0.87 (0.78-0.96)
Cardiac disorders	2,589	0.67 (0.64-0.70)	2,583	0.85 (0.81-0.88)	2,589	0.67 (0.64-0.70)	2,238	0.97 (0.86-1.09)	328	0.68 (0.61-0.77)
Congenital, familial and genetic disorders	36	0.18 (0.13-0.25)	36	0.21 (0.15-0.29)	36	0.28 (0.20-0.39)	34	1.06 (0.25-4.41)	5	0.70 (0.27-1.80)
Ear and labyrinth disorders	226	0.54 (0.48-0.62)	226	0.54 (0.47-0.62)	226	0.62 (0.54-0.72)	196	0.97 (0.66-1.43)	52	1.26 (0.92-1.73)
Endocrine disorders	2,863	<b>6.91 (6.60-7.23)</b>	2,856	<b>6.69 (6.38-7.02)</b>	2,863	<b>3.99 (3.69-4.30)</b>	2,275	0.88 (0.80-0.97)	744	<b>1.60 (1.46-1.75)</b>
Eye disorders	1,194	0.69 (0.65-0.73)	1,192	0.68 (0.64-0.72)	1,194	0.66 (0.62-0.70)	1,067	1.00 (0.83-1.21)	271	<b>1.21 (1.05-1.39)</b>
Gastrointestinal disorders	9,124	0.82 (0.80-0.84)	9,094	0.85 (0.83-0.87)	9,124	0.91 (0.89-0.94)	7,773	0.95 (0.88-1.01)	2,803	<b>2.03 (1.93-2.15)</b>
General disorders and administration site conditions	16,449	0.80 (0.78-0.81)	16,420	0.76 (0.74-0.77)	16,449	0.93 (0.91-0.95)	15,066	1.04 (0.98-1.11)	2,894	0.87 (0.82-0.91)
Hepatobiliary disorders	2,632	<b>1.33 (1.28-1.39)</b>	2,622	<b>1.45 (1.39-1.51)</b>	2,632	<b>1.32 (1.26-1.38)</b>	2,149	0.91 (0.82-1.01)	426	0.94 (0.84-1.04)
Immune system disorders	820	0.51 (0.48-0.55)	817	0.52 (0.48-0.56)	820	0.48 (0.45-0.52)	730	1.00 (0.80-1.24)	138	0.89 (0.74-1.08)
Infections and infestations	5,795	0.68 (0.67-0.70)	5,781	0.73 (0.71-0.76)	5,795	0.59 (0.57-0.60)	5,036	0.97 (0.89-1.05)	1,063	1.00 (0.93-1.07)
Injury, poisoning and procedural complications	6,776	<b>1.20 (1.17-1.23)</b>	6,767	<b>1.13 (1.10-1.16)</b>	6,776	<b>1.09 (1.06-1.12)</b>	6,185	1.03 (0.94-1.12)	797	0.57 (0.53-0.62)
Investigations	5,147	0.63 (0.61-0.65)	5,123	0.70 (0.68-0.72)	5,147	0.71 (0.69-0.74)	4,588	1.00 (0.91-1.10)	984	1.02 (0.94-1.10)
Metabolism and nutrition disorders	4,196	1.03 (1.00-1.07)	4,180	<b>1.13 (1.10-1.17)</b>	4,196	<b>1.05 (1.01-1.08)</b>	3,496	0.93 (0.85-1.01)	840	<b>1.15 (1.06-1.25)</b>
Musculoskeletal and connective tissue disorders	3,759	0.89 (0.86-0.92)	3,751	0.86 (0.83-0.89)	3,759	0.97 (0.93-1.00)	3,332	0.99 (0.89-1.10)	539	0.75 (0.68-0.83)

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 2 (continued).**

	ICI vs other anticancer drugs (Q2/2004-Q2/2018)		ICIs vs other anticancer drugs (Q2/2011-Q2/2018)		ICIs vs monoclonal antibodies (Q2/2004-Q2/2018)		monotherapy vs combination (n=42,156)		Anti-CTLA4 monotherapy vs anti-PD1/PDL1 monotherapy (n=8,903)	
	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)	N	ROR (95%CI)
<b>Toxicity of interest</b>										
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	8,773	<b>1.85 (1.81-1.90)</b>	8,762	<b>1.85 (1.80-1.89)</b>	8,773	<b>1.67 (1.63-1.72)</b>	8,064	1.04 (0.96-1.13)	1,380	0.78 (0.73-0.83)
Nervous system disorders	5,402	0.71 (0.69-0.73)	5,386	0.76 (0.74-0.78)	5,402	0.76 (0.73-0.78)	4,817	1.00 (0.91-1.10)	1,088	1.08 (1.00-1.16)
Pregnancy, puerperium and perinatal conditions	50	0.29 (0.22-0.38)	50	0.31 (0.23-0.40)	50	0.32 (0.24-0.43)	27	0.61 (0.35-1.06)	13	<b>2.28 (1.07-4.86)</b>
Product issues	51	0.23 (0.17-0.30)	51	0.22 (0.17-0.29)	51	0.27 (0.20-0.36)	51	NA	3	NC
Psychiatric disorders	1,432	0.61 (0.58-0.65)	1,423	0.63 (0.60-0.67)	1,432	0.78 (0.74-0.83)	1,303	1.02 (0.85-1.23)	254	0.92 (0.80-1.06)
Renal and urinary disorders	2,377	0.87 (0.83-0.91)	2,370	0.96 (0.92-1.00)	2,377	0.90 (0.86-0.95)	2,060	0.97 (0.86-1.10)	365	0.83 (0.74-0.93)
Reproductive system and breast disorders	188	0.44 (0.38-0.51)	187	0.46 (0.40-0.53)	188	0.50 (0.43-0.58)	170	1.01 (0.62-1.65)	23	0.64 (0.41-0.99)
Respiratory, thoracic and mediastinal disorders	7,240	<b>1.04 (1.01-1.06)</b>	7,227	<b>1.15 (1.12-1.18)</b>	7,240	0.92 (0.90-0.95)	6,473	1.00 (0.92-1.09)	728	0.49 (0.45-0.53)
Skin and subcutaneous tissue disorders	4,618	0.66 (0.64-0.68)	4,614	0.64 (0.62-0.66)	4,618	0.83 (0.80-0.86)	4,128	1.00 (0.91-1.11)	1,084	<b>1.28 (1.19-1.37)</b>
Social circumstances	107	0.25 (0.20-0.30)	107	0.26 (0.21-0.31)	107	0.38 (0.31-0.46)	104	1.09 (0.35-3.44)	15	0.68 (0.39-1.18)
Surgical and medical procedures	1,298	<b>1.20 (1.13-1.27)</b>	1,298	<b>1.37 (1.30-1.45)</b>	1,298	<b>1.64 (1.53-1.75)</b>	1,180	1.02 (0.84-1.24)	186	0.74 (0.63-0.87)
Vascular disorders	1,845	0.49 (0.46-0.51)	1,836	0.56 (0.53-0.58)	1,845	0.43 (0.41-0.45)	1,632	0.99 (0.86-1.15)	378	1.10 (0.98-1.24)

NC: not calculated because the number of cases was <5 (see methods for details).

NA: not applicable because the ROR cannot be calculated (no cases in combination regimen).

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 3.** Disproportionality analysis in FAERS (ICIs compared to other oncological agents) and literature appraisal. OoSRS: overview of systematic reviews. Top priorities are shown with a dark background.

System Organ Class	FAERS*	Literature appraisal (OoSRS)				COMBINED ASSESSMENT
		Outcome investigated as for the original studies	N. of studies on the outcome of interest	N. of positive/neutral/negative studies	Evaluation	
Blood and lymphatic system disorders	x	Anemia, neutropenia, leukopenia, hypophosphatemia, lymphopenia, thrombocytopenia	6	0/0/6	CONSISTENT NEGATIVE ASSOCIATION	LOW PRIORITY
Cardiac disorders	x	Cardiorespiratory arrest, cardiac failure, myocardial infarction, stroke	2	0/1/1	UNCERTAIN ASSOCIATION	LOW PRIORITY
Endocrine disorders	√	Hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, thyroiditis	9	9/0/0	CONSISTENT POSITIVE ASSOCIATION	TOP PRIORITY
Eye disorders	x	Uveitis, dry eyes	1	1/0/0	UNCERTAIN ASSOCIATION	LOW PRIORITY
Gastrointestinal disorders	x	Colitis, diarrhea, nausea, vomiting	11	6/2/3	CONSISTENT POSITIVE ASSOCIATION	INTERMEDIATE PRIORITY
General disorders and administration site conditions	x	Fatigue, asthenia	7	0/3/4	CONSISTENT NEGATIVE ASSOCIATION	LOW PRIORITY
Hepatobiliary disorders	√	Increased transaminases, hepatitis	9	6/3/0	CONSISTENT POSITIVE ASSOCIATION	TOP PRIORITY

\* x= no statistically significant disproportionality emerged in primary analysis; √= statistically significant disproportionality emerged in primary analysis. See table 2 for details.

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 3 (continued).**

System Organ Class	FAERS*	Literature appraisal (OoSRs)				COMBINED ASSESSMENT
		Outcome investigated as for the original studies	N. of studies on the outcome of interest	N. of positive studies	Evaluation	
Injury, poisoning and procedural complications	√					HIGH PRIORITY
Investigations	x	Lipase increased	1	0/1/0	UNCERTAIN ASSOCIATION	LOW PRIORITY
Musculoskeletal and connective tissue disorders	x	Arthritis, vasculitis, myositis	1	0/0/1	UNCERTAIN ASSOCIATION	LOW PRIORITY
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	√					HIGH PRIORITY
Respiratory, thoracic and mediastinal disorders	√	Pneumonitis, interstitial lung disease	10	7/3/0	CONSISTENT POSITIVE ASSOCIATION	TOP PRIORITY
Skin and subcutaneous tissue disorders	x	Rash, pruritus, vitiligo, dermatitis	13	9/3/1	CONSISTENT POSITIVE ASSOCIATION	INTERMEDIATE PRIORITY
Surgical and medical procedures	√					HIGH PRIORITY

\* x= no statistically significant disproportionality emerged in primary analysis; √= statistically significant disproportionality emerged in primary analysis. See table 2 for details.



16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4.** Toxicities emerging as top and high priority: disproportionality analyses performed on the 2004Q1-2018Q2 period at PT level (signs/symptoms) and distinguishing anti-CTLA4 from anti-PD1/PDL1 agents (see methods for details). In bold: statistically-significant ROR (i.e., lower limit of the 95%CI of the ROR>1). Only top 10 adverse events are listed in decreasing order of frequency (ICI as a class). The sum of the number of cases for the different groups of ICI may be higher than total number of cases for the drug class because a patient may have received more than one drug (anticancer combination regimen). The full list of adverse events is provided in supplementary material 2. Largest differences in terms of frequency between anti-CTLA4 and anti-PD1/PDL1 drugs (ROR value at least 2-fold higher) are shown as gray background.

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
<b>Endocrine disorders</b>						
Hypothyroidism	777	<b>6.36 (5.85-6.93)</b>	214	<b>5.92 (5.15-6.82)</b>	680	<b>6.87 (6.29-7.50)</b>
Hypophysitis	594	<b>20.80 (11.13-38.86)</b>	466	<b>56.39 (46.6-68.24)</b>	284	<b>12.19 (10.38-14.3)</b>
Adrenal insufficiency	493	<b>10.03 (8.88-11.33)</b>	264	<b>18.33 (15.92-21.1)</b>	346	<b>8.66 (7.61-9.86)</b>
Hyperthyroidism	422	<b>10.09 (8.84-11.52)</b>	159	<b>12.89 (10.85-15.32)</b>	370	<b>10.91 (9.54-12.47)</b>
Hypopituitarism	197	<b>16.60 (12.23-22.53)</b>	128	<b>36.67 (28.58-47.04)</b>	110	<b>11.40 (8.88-14.65)</b>
Thyroiditis	170	<b>12.91 (10.13-16.46)</b>	74	<b>19.05 (14.59-24.88)</b>	147	<b>13.76 (10.86-17.44)</b>
Thyroid disorder	151	<b>4.09 (3.42-4.88)</b>	43	<b>3.94 (2.89-5.36)</b>	127	<b>4.24 (3.50-5.12)</b>
Autoimmune thyroiditis	89	<b>9.60 (7.24-12.74)</b>	30	<b>10.95 (7.42-16.17)</b>	78	<b>10.37 (7.78-13.82)</b>
Endocrine disorder	65	<b>12.59 (8.57-18.51)</b>	47	<b>30.87 (21.09-45.17)</b>	29	<b>6.92 (4.52-10.59)</b>
Hypothalamo-pituitary disorder	63	<b>14.02 (9.12-21.56)</b>	40	<b>30.17 (20.04-45.42)</b>	39	<b>10.69 (7.09-16.12)</b>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4 (continued).**

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
<i>Hepatobiliary disorders</i>						
Hepatitis	420	<b>3.12 (2.81-3.47)</b>	188	<b>4.75 (4.09-5.52)</b>	333	<b>3.05 (2.72-3.42)</b>
Hepatic function abnormal	385	<b>1.55 (1.39-1.72)</b>	75	1.02 (0.81-1.28)	364	<b>1.80 (1.62-2.01)</b>
Autoimmune hepatitis	373	<b>14.23 (11.90-17)</b>	161	<b>20.85 (17.34-25.07)</b>	303	<b>14.24 (12.04-16.84)</b>
Liver disorder	241	<b>1.18 (1.04-1.35)</b>	102	<b>1.70 (1.39-2.07)</b>	196	<b>1.19 (1.03-1.37)</b>
Hepatic failure	193	0.91 (0.78-1.05)	72	1.14 (0.91-1.45)	151	0.87 (0.74-1.03)
Hepatotoxicity	154	1.04 (0.88-1.22)	70	<b>1.59 (1.26-2.02)</b>	116	0.96 (0.80-1.16)
Drug-induced liver injury	123	<b>2.37 (1.96-2.86)</b>	47	<b>3.06 (2.28-4.10)</b>	102	<b>2.42 (1.97-2.96)</b>
Hepatocellular injury	117	<b>1.45 (1.20-1.75)</b>	42	<b>1.76 (1.30-2.40)</b>	97	<b>1.48 (1.21-1.82)</b>
Cholestasis	116	<b>1.41 (1.17-1.70)</b>	36	<b>1.48 (1.06-2.06)</b>	101	<b>1.51 (1.24-1.85)</b>
Cholangitis	110	<b>2.11 (1.73-2.57)</b>	11	0.71 (0.39-1.29)	106	<b>2.51 (2.05-3.07)</b>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4 (continued).**

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
<i>Respiratory disorders</i>						
Dyspnoea	1,614	0.91 (0.87-0.96)	411	0.78 (0.71-0.86)	1,423	0.99 (0.94-1.05)
Pneumonitis	1,289	<b>4.06 (3.82-4.32)</b>	304	<b>3.22 (2.87-3.62)</b>	1,196	<b>4.66 (4.38-4.97)</b>
Interstitial lung disease	794	<b>1.63 (1.52-1.75)</b>	74	0.51 (0.40-0.64)	761	<b>1.93 (1.79-2.08)</b>
Pleural effusion	656	0.97 (0.90-1.05)	136	0.68 (0.57-0.81)	598	<b>1.09 (1.01-1.19)</b>
Cough	646	0.88 (0.82-0.96)	128	0.59 (0.49-0.70)	580	0.98 (0.90-1.06)
Respiratory failure	537	1.08 (0.99-1.18)	103	0.70 (0.58-0.85)	482	<b>1.20 (1.09-1.31)</b>
Pulmonary embolism	413	0.80 (0.72-0.88)	131	0.86 (0.72-1.02)	325	0.77 (0.69-0.87)
Lung disorder	330	<b>1.28 (1.14-1.43)</b>	37	0.48 (0.35-0.67)	311	<b>1.49 (1.33-1.67)</b>
Haemoptysis	256	<b>1.54 (1.36-1.75)</b>	29	0.59 (0.41-0.85)	241	<b>1.79 (1.57-2.04)</b>
Hypoxia	217	0.96 (0.84-1.10)	61	0.91 (0.71-1.18)	198	1.08 (0.94-1.25)

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4 (continued).**

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
<i>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</i>						
Malignant neoplasm progression	6,691	<b>5.94 (5.77-6.12)</b>	1,416	<b>4.06 (3.84-4.3)</b>	5,806	<b>6.42 (6.23-6.63)</b>
Metastases to central nervous system	343	<b>2.03 (1.81-2.27)</b>	132	<b>2.65 (2.22-3.15)</b>	252	<b>1.83 (1.61-2.09)</b>
Neoplasm malignant	280	1.11 (0.98-1.25)	229	<b>3.10 (2.72-3.55)</b>	53	0.26 (0.20-0.34)
Neoplasm progression	140	0.36 (0.31-0.43)	45	0.40 (0.30-0.53)	102	0.33 (0.27-0.40)
Metastases to bone	105	0.85 (0.70-1.04)	21	0.58 (0.37-0.89)	98	0.98 (0.80-1.20)
Metastases to liver	94	0.52 (0.42-0.63)	39	0.72 (0.53-0.99)	74	0.50 (0.40-0.63)
Tumour pseudoprogression	94	<b>17.42 (10.64-28.52)</b>	8	<b>5.01 (2.44-10.28)</b>	94	<b>21.47 (13.11-35.15)</b>
Metastases to lung	81	0.60 (0.48-0.75)	36	0.91 (0.65-1.26)	64	0.59 (0.46-0.75)
Neoplasm	79	0.91 (0.73-1.15)	28	1.10 (0.76-1.59)	60	0.86 (0.66-1.11)
Tumour haemorrhage	68	<b>1.70 (1.33-2.18)</b>	22	<b>1.86 (1.22-2.85)</b>	53	<b>1.64 (1.24-2.16)</b>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4 (continued).**

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
<i><b>Injury, poisoning and procedural complications</b></i>						
Product use in unapproved indication	1,734	<b>6.29 (5.94-6.66)</b>	312	<b>3.77 (3.36-4.23)</b>	1,687	<b>7.60 (7.17-8.04)</b>
Product use issue	1,365	<b>3.99 (3.76-4.23)</b>	69	0.67 (0.52-0.84)	1,342	<b>4.86 (4.58-5.16)</b>
Off label use	1,183	0.88 (0.83-0.93)	266	0.67 (0.59-0.75)	1,015	0.93 (0.88-0.99)
Infusion related reaction	365	1.05 (0.94-1.16)	79	0.77 (0.61-0.96)	315	1.11 (0.99-1.25)
Fall	320	0.6 (0.54-0.67)	78	0.49 (0.39-0.62)	263	0.61 (0.54-0.69)
Prescribed overdose	262	<b>14.64 (11.75-18.24)</b>	232	<b>44.34 (35.99-54.63)</b>	51	<b>3.50 (2.60-4.70)</b>
Incorrect product storage	241	<b>6.25 (5.38-7.27)</b>	50	<b>4.38 (3.29-5.84)</b>	201	<b>6.42 (5.48-7.54)</b>
Inappropriate schedule of drug administration	180	<b>1.67 (1.43-1.94)</b>	17	0.53 (0.33-0.86)	177	<b>2.02 (1.73-2.36)</b>
Toxicity to various agents	174	0.41 (0.35-0.47)	79	0.63 (0.5-0.78)	114	0.33 (0.27-0.4)
Drug dose omission	137	0.49 (0.41-0.58)	18	0.22 (0.14-0.34)	120	0.53 (0.44-0.63)

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 4 (continued).**

Toxicity	ICI as class vs other anticancer agents		Anti-CTLA4 vs other anticancer agents, including anti-PD1/PDL1 drugs		Anti-PD1/PDL1 vs other anticancer agents, including anti-CTLA4 drugs	
	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)	N. cases	ROR (95%CI)
Surgical and medical procedures	172	<b>5.19 (4.37-6.16)</b>	37	<b>3.77 (2.71-5.25)</b>	155	<b>5.76 (4.82-6.89)</b>
Transfusion	172	<b>5.19 (4.37-6.16)</b>	37	<b>3.77 (2.71-5.25)</b>	155	<b>5.76 (4.82-6.89)</b>
Hospitalisation	139	0.82 (0.69-0.97)	56	1.12 (0.86-1.45)	103	0.75 (0.61-0.91)
Hospice care	99	3.10 (2.50-3.83)	16	<b>1.69 (1.03-2.78)</b>	93	<b>3.59 (2.88-4.46)</b>
Surgery	98	<b>1.46 (1.19-1.79)</b>	21	1.05 (0.69-1.62)	82	<b>1.50 (1.2-1.88)</b>
Therapy cessation	55	0.95 (0.73-1.25)	22	1.29 (0.85-1.97)	33	0.71 (0.50-1.00)
Packed red blood cell transfusion	47	<b>7.62 (5.32-10.91)</b>	10	<b>5.48 (2.88-10.46)</b>	43	<b>8.59 (5.96-12.39)</b>
Platelet transfusion	33	4.31 (2.94-6.33)	5	2.21 (0.91-5.38)	31	<b>4.99 (3.37-7.39)</b>
Dialysis	26	0.54 (0.36-0.79)	3	NC	23	0.58 (0.39-0.88)
Thoracic cavity drainage	26	<b>7.15 (4.45-11.49)</b>	1	NC	25	<b>8.47 (5.25-13.68)</b>
Cardiac pacemaker insertion	23	<b>2.88 (1.85-4.47)</b>	6	<b>2.54 (1.12-5.74)</b>	21	<b>3.24 (2.05-5.12)</b>

NC: not calculated because the number of cases was <5 (see methods for details).

## References

1. Clarke JM, George DJ, Lisi S, Salama AKS. Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. *Target Oncol.*2018;13:1-20
2. Martin-Liberal J, Hierro C, Ochoa de OM, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. *Target Oncol.*2017;12:125-38
3. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. *Nat Rev Drug Discov.*2016;15:235-47
4. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. *JAMA Oncol.*2016;2:1346-53
5. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralknik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Jr., Anders RA, Sosman JA, Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med.*2016;375:1749-55
6. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med.*2018;378:158-68
7. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter CJ, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.*2018;36:1714-68
8. Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. *Lancet Oncol.*2019;20:e54-e64
9. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nat Rev Clin Oncol.*2016;13:473-86
10. Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. *Intern Emerg Med.*2018;13:1-9
11. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. *BMJ.*2018;360:k793
12. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. *Ann Intern Med.*2018;168:121-30
13. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet.*2018;391:933
14. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S. Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. *Target Oncol.*2018;13:509-515
15. Centanni M, Moes DJAR, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. *Clin Pharmacokinet.*2019; Feb 28. doi: 10.1007/s40262-019-00748-2
16. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. *Int J Med Sci.*2013;10:796-803
17. Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. *Drug Saf.*2010;33:865-78

18. Cutroneo PM, Isgro V, Russo A, Ientile V, Sottosanti L, Pimpinella G, Conforti A, Moretti U, Caputi AP, Trifiro G. Safety profile of biological medicines as compared with non-biologicals: an analysis of the Italian spontaneous reporting system database. *Drug Saf.*2014;37:961-70
19. Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Reglat A, Pariente A, Aparicio T, Miremont-Salame G, Noize P. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. *Target Oncol.*2017;12:805-14
20. Araujo AGS, Borba HHL, Tonin FS, Lenzi L, Venson R, Pontarolo R, Wiens A. Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). *BioDrugs.*2018;32:377-90
21. Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, Moretti U. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. *Nutr Metab Cardiovasc Dis.*2018;28:533-542
22. Fukazawa C, Hinomura Y, Kaneko M, Narukawa M. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA. *Pharmacoepidemiol Drug Saf.*2018;27:1402-8
23. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. *Clin Pharmacol Ther.*2013;93:539-46
24. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A, editor. *Data mining applications in engineering and medicine.* Croatia: InTech; 2012. p. 265-302
25. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiol Drug Saf.*2009;18:427-36
26. Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, Blandizzi C. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. *Expert Rev Clin Pharmacol.*2015;8:61-75
27. Slattery J, Alvarez Y, Hidalgo A. Choosing thresholds for statistical signal detection with the proportional reporting ratio. *Drug Saf.*2013;36:687-92
28. Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. *Ther Adv Drug Saf.*2017;8:145-56
29. Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The Global Evidence Mapping Initiative: scoping research in broad topic areas. *BMC Med Res Methodol.*2011;11:92
30. Baraibar I, Melero I, Ponz-Sarvisé M, Castanon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. *Drug Saf.*2019 Jan 16. doi: 10.1007/s40264-018-0774-8
31. Khoja L, Day D, Wei-Wu CT, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. *Ann Oncol.*2017;28:2377-85
32. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. *BMJ.*2018;363:k4226
33. Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. *Pharmacotherapy.*2017;37:1383-90
34. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moshley JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol.*2018;4:1721-8
35. Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. *Clin Drug Investig.*2019 Jan 23. doi: 10.1007/s40261-018-0735-0
36. Macia-Martinez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. *Drug Saf.*2016;39:29-43



- 1 37. Sosa A, Lopez CE, Simon OC, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. *Ther Adv Med Oncol.*2018;10:1758835918764628
- 2
- 3 38. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving  
4 picture of risk associated with a vital class of immunotherapy agents. *Liver Int.*2018;38:976-87
- 5 39. De Martin E., Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A,  
6 Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D. Characterization of liver injury induced by cancer  
7 immunotherapy using immune checkpoint inhibitors. *J Hepatol.*2018;68:1181-1190
- 8
- 9 40. Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors:  
10 A systematic review and meta-analysis of published data. *Int J Cancer.*2017;141:1018-28
- 11 41. Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver  
12 disease: a novel form of serious liver injury. *Ann Oncol.*2017;28:671-2
- 13 42. Gelsomino F, Vitale G, Ardizzoni A. Immune-mediated cholangitis: is it always nivolumab's fault? *Cancer Immunol*  
14 *Immunother.*2018;67:1325-1327
- 15 43. Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T,  
16 Sato T, Kudo M, Ito A, Nakagawa K. Imaging and clinicopathological features of nivolumab-related cholangitis in  
17 patients with non-small cell lung cancer. *Invest New Drugs.*2017;35:529-36
- 18 44. Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as  
19 second-line chemotherapy for advanced non-small-cell lung cancer: a case report. *Cancer Immunol*  
20 *Immunother.*2018;67:61-5
- 21 45. Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for  
22 the right tools for a correct diagnosis of this rare immune-related adverse event. *Invest New Drugs.*2018;36:144-  
23 6
- 24 46. Ogawa K, Kamimura K, Terai S. Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing  
25 Cholangitis. *Hepatology.*2018;69:914-916
- 26 47. Noda-Narita S, Mizuno S, Noguchi S, Watanabe K, Nakai Y, Koike K, Kage H, Nagase T. Development of mild drug-  
27 induced sclerosing cholangitis after discontinuation of nivolumab. *Eur J Cancer.*2019;107:93-6
- 28 48. Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, Barnhart H, Hoofnagle  
29 JH. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.  
30 *Hepatology.*2017;65:1267-77
- 31 49. Misu T, Kortepeter CM, Munoz MA, Wu E, Dal Pan GJ. An Evaluation of "Drug Ineffective" Postmarketing Reports  
32 in Drug Safety Surveillance. *Drugs Real World Outcomes.*2018;
- 33 50. Juhlin K, Karimi G, Ander M, Camilli S, Dheda M, Har TS, Isahak R, Lee SJ, Vaughan S, Caduff P, Noren GN. Using  
34 VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites. *Drug Saf.*2015;38:373-82
- 35 51. Trippe ZA, Brendani B, Meier C, Lewis D. Identification of Substandard Medicines via Disproportionality Analysis  
36 of Individual Case Safety Reports. *Drug Saf.*2017;40:293-303
- 37 52. Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic  
38 review. *Br J Clin Pharmacol.*2017;83:227-46
- 39 53. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A,  
40 Soria JC, Ferte C. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-  
41 PD-1/PD-L1. *Clin Cancer Res.*2017;23:1920-8
- 42 54. Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. *J Clin*  
43 *Oncol.*2015;33:3541-3
- 44 55. Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H,  
45 Nakanishi M, Yamamoto N. Correlation between immune-related adverse events and efficacy in non-small cell  
46 lung cancer treated with nivolumab. *Lung Cancer.*2018;115:71-4
- 47 56. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M,  
48 Nakagawa K. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung  
49 Cancer. *JAMA Oncol.*2018;4:374-8
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

57. Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. *J Thorac Oncol.*2017;12:1798-805

58. Michel C, Scosyrev E, Petrin M, Schmouder R. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? *Clin Drug Investig.*2017;37:415-22

59. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. *JAMA Oncol.*2018;4:1112-1115

60. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. *Lancet Oncol.*2018;19:1579-89

61. Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. *Ther Clin Risk Manag.*2017;13:1195-203

62. Trifiro G, Sultana J, Bate A. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. *Drug Saf.*2018;41:143-9

63. Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, Joosten P, Storm H, van Roon EN, Hoogendoorn M. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology. *Eur J Cancer.*2017;86:178-85

**Flow Chart to compare FAERS analysis with Literature assessment.** ICI: immune checkpoint inhibitor; SRs: systematic reviews.

\* Primary Suspect or Secondary Suspect (see text for details). RCTs: randomized controlled trials.






Figure 2



Endocrine disorders  
(N=2,863)

Hepatobiliary disorders  
(N=2,632)



Respiratory, thoracic and mediastinal disorders  
(N=7,242)